Manu Vandijck
Overview
Explore the profile of Manu Vandijck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
944
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ashton N, Keshavan A, Brum W, Andreasson U, Arslan B, Droescher M, et al.
Alzheimers Dement
. 2025 Feb;
21(2):e14508.
PMID: 39907496
Introduction: The Alzheimer's Association Global Biomarker Standardization Consortium conducted a blinded case-control study to learn which phosphorylated tau (p-tau) assays provide the largest fold-changes in Alzheimer's disease (AD) versus non-AD...
2.
Wojdala A, Vanbrabant J, Bayoumy S, Antwi-Berko D, Le Bastard N, van der Flier W, et al.
Alzheimers Res Ther
. 2024 Dec;
16(1):266.
PMID: 39702308
Background: Among the Alzheimer's disease (AD) biomarkers measured in blood, phosphorylated forms of tau (p-tau) have been shown to exhibit a particularly high diagnostic potential. Here, we performed a comprehensive...
3.
Ashton N, Keshavan A, Brum W, Andreasson U, Arslan B, Droescher M, et al.
medRxiv
. 2024 Sep;
PMID: 39228740
Background: Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer's disease (AD) pathology. Multiple p-tau biomarkers on several analytical platforms are poised for clinical use. The Alzheimer's Association Global...
4.
Nisenbaum L, Martone R, Chen T, Rajagovindan R, Dent G, Beaver J, et al.
Alzheimers Dement
. 2023 Feb;
19(8):3379-3388.
PMID: 36795603
Introduction: We assessed the use of cerebrospinal fluid (CSF) biomarkers as an alternative to positron emission tomography (PET) for brain amyloid beta (Aβ) pathology confirmation in the EMERGE and ENGAGE...
5.
Wilson E, Young C, Ramos Benitez J, Swarovski M, Feinstein I, Vandijck M, et al.
Alzheimers Res Ther
. 2022 Nov;
14(1):172.
PMID: 36371232
Background: The recent promise of disease-modifying therapies for Alzheimer's disease (AD) has reinforced the need for accurate biomarkers for early disease detection, diagnosis and treatment monitoring. Advances in the development...
6.
Nojima H, Ito S, Kushida A, Abe A, Motsuchi W, Verbel D, et al.
Ann Clin Transl Neurol
. 2022 Nov;
9(12):1898-1909.
PMID: 36321325
Objectives: Cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) are well-established in research settings, but their use in routine clinical practice remains a largely unexploited potential. Here, we examined the...
7.
Ohrfelt A, Benedet A, Ashton N, Kvartsberg H, Vandijck M, Weiner M, et al.
Neurology
. 2022 Oct;
100(3):e275-e285.
PMID: 36192174
Background And Objectives: To test the associations between the presynaptic growth-associated protein 43 (GAP-43), quantified in CSF, and biomarkers of Alzheimer disease (AD) pathophysiology, cross-sectionally and longitudinally. Methods: In this...
8.
Janelidze S, Bali D, Ashton N, Barthelemy N, Vanbrabant J, Stoops E, et al.
Brain
. 2022 Sep;
146(4):1592-1601.
PMID: 36087307
Plasma phospho-tau (p-tau) species have emerged as the most promising blood-based biomarkers of Alzheimer's disease. Here, we performed a head-to-head comparison of p-tau181, p-tau217 and p-tau231 measured using 10 assays...
9.
Gobom J, Parnetti L, Rosa-Neto P, Vyhnalek M, Gauthier S, Cataldi S, et al.
Clin Chem Lab Med
. 2021 Nov;
60(2):207-219.
PMID: 34773730
Objectives: The core cerebrospinal fluid (CSF) biomarkers; total tau (tTau), phospho-tau (pTau), amyloid β 1-42 (Aβ 1-42), and the Aβ 1-42/Aβ 1-40 ratio have transformed Alzheimer's disease (AD) research and...
10.
Hansson O, Batrla R, Brix B, Carrillo M, Corradini V, Edelmayer R, et al.
Alzheimers Dement
. 2021 Mar;
17(9):1575-1582.
PMID: 33788410
The core cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarkers amyloid beta (Aβ42 and Aβ40), total tau, and phosphorylated tau, have been extensively clinically validated, with very high diagnostic performance for...